1Voelkcl NF,Quaife RA,Leinwand LA,et al.Right ventricular function and failure:report of a National Heart,Lung,and Blood Institute working group on cellular and molecular mechanisms of right heart failure[J].Circulation,2006.114(17):1883-1891. 被引量：1
3Rich S,aufmann E,Levy PS.The effect of high doses of calcium channel blockers on survival in primary pulmonary hypertension[J].N Engl J Med,1992.327(2):76-81. 被引量：1
4Sitbon O,Humbert M,Jais X,et al.Long-term response to calcium channel blockers in idiopathic pulmonary arterial hypertension[J].Circulation,2005,111(21):3105-3111. 被引量：1
5Humbert M,Mo-eU NW,Amber SL.et al.Cellular and molecular pathobiology of pulmonary artefiM hypertension[J].JAm Coll Cardio,2004,43(3):13S-24S. 被引量：1
6Thomson JR,Manhado RD,Pauciulo MW,et al.Sporadic pri-mary pulmonary hypertension is associatedwith germline muta-tions of the gene encoding BM PR-Ⅱ.a receptormember of the TGF-b family[J].J Med Genet,2000,37(10):741-745. 被引量：1
7Botney MD,Kaiser LR,Cooper JD,et al.Extraeellular matrix protein gene expression in atherosclerotic hypertensive pulmonary arterise[J].Am J Pathol,1992,151(2):1019-1025. 被引量：1
8Yi ES,Kiln H,Aim H,et al.Distribution of obstructive intimal lesions and their cellular phenotypes in chronic pulmonary hypertension[J].Am J Respir Crit Care Med,2000,162(4):1577-1586. 被引量：1
9Botney MD.Role of hemodynamics in pulmonary vascular remodeling[J].Am J Respir Crit Care Med.1999,159(2):361-364. 被引量：1
10Okada K,Tanaka Y,Bernstein M,et al.Pulmonary hemodynamics modify the rat pulmonary artery response to injury.A neointimal model ofpumonsry hypertension[J].Am J Pathol,1997,51(4):1019-1025. 被引量：1
2Thistlethwaite PA, Mo M, Madani MM, et al. Operative classification of thromboembolic disease determines outcome after pulmonary endarterectomy. J Thorac Cardiovasc Surg, 2002,124: 1203-1211. 被引量：1
7Reichenberger F, Voswinckel R, Enke B, et al. long-term treatment with sildenafil in chronic thromboembolic pulmonary hypertension. Eur Respir J,2007,30:922-927. 被引量：1
8Bresser P, Pepke-Zaba J, Jais X, et al. Medical therapies for chronic thromboembolic pulmonary hypertension: an evolving treatment paradigm. Proc Am Thorac Soc ,2006, 3:594-600. 被引量：1
9Huges R j, Jais X, Bonderman D, et al. The efficacy of bosentan in inoperable chronic thromboembolic pulmonary hypertension: a 1-year follow-up study. Eur Respir J,2006, 28 : 138-143. 被引量：1
8Postma D S, Reddel H K, Ten Hacken N H, et al. Asthma and chronic obstructive pulmonary disease:similarities and differences [J]. Clin Chest Med,2014,35(l) : 143-156. 被引量：1
9O'donnell D E, Laveneziana P, Webb K, et al. Chronic obstructive pulmonary disease: clinical integrative physiology [ J ]. Clin Chest Med,2014,35(1) :51-69. 被引量：1
10Mandegar M, Yuan J X. Role of K: channels in pulmonary hy- pertension[ J]. Vaseul Pharmacol, 2002,38 (1) : 25-33. 被引量：1
